drugset / Trial / NCT05070598
Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety, or affect the patient's completion of the study (such as uncontrolled hypertension, diabetes, thyroid disease, etc.);
Timeline
- Start
- 2021-09-07
- Primary completion
- 2023-09-01
- Completion
- 2024-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pyrotinib | Small molecule | — | — |
| Subject | Tegafur | Unknown | — | — |
Indications
No indication recorded.